Twist Bioscience Expands Express Genes Rapid Synthesis Service
January 24 2024 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the expansion of
Twist Express Genes, a new leading gene synthesis service with an
order to shipping turnaround starting at five business days1, to
include larger DNA preparations up to 1 milligram.
The Express Genes offering, initially launched in November 2023,
now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg
to 1mg) DNA preparations. As with Twist standard speed Clonal
Genes, all Twist Express Genes are NGS-verified as clonally
perfect.
“Since the initial launch of our Express Genes service in
November, we have received positive and enthusiastic feedback from
existing customers on our consistent and rapid turnaround time. By
expanding Express Genes to include midiprep and maxiprep, we can
now offer rapid gene synthesis at all gene prep scales, enabling
large scale experimentation for pharmaceutical, biotechnology,
academic and industrial chemical researchers,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With the
expanded offering of Twist Express Genes, more researchers can gain
access to Twist genes fast and at scale, including those using
alternative providers and those cloning their own genes. The
ability to order and receive synthetic DNA fast and at scale means
more time for cutting-edge research, more make-test-learn cycles,
and an accelerated journey to game-changing discoveries.”
Twist leverages its ability to miniaturize the chemical reaction
to create DNA using its silicon-based DNA synthesis platform along
with expertise, software, optimized processes and the expanded
layout of its Wilsonville facility to deliver Clonal Genes and Gene
Fragments at scale and with rapid turnaround times. Twist’s Express
Genes are offered with dynamic pricing, which reflects market
demand and manufacturing capacity in a responsive premium price.
Customers are able to quickly and easily place orders for Express
Genes through Twist’s ecommerce platform.
Twist Express Genes
Twist Express Genes are 0.3kb to 5.0kb in length. Due to scale
enabled by Twist’s platform, orders of any size both small and
large can be filled, and as with standard speed Twist Clonal Genes,
Twist Express Genes are NGS sequence-verified as one hundred
percent accurate. Twist Express Genes can be cloned into catalog
vectors or custom vectors so that customers can move right to
experimentation. They can also be shipped in customers’ preferred
delivery formats, including tubes and plates. For more information
and product specifications click here.
Current turnaround times for some Twist Bioscience
products:
- Express Genes1 (50ng-10µg): starting at 5 business days, now
for up to 10µg
- Standard Clonal Genes (50ng-10µg): starting at 10 business
days
- Express Genes1 (10µg-1mg): starting at 8 business days
- Standard Clonal Genes (10µg-1mg): starting at 13 business
days
Twist quantified the minimal carbon footprint of manufacturing a
single gene in its 2023 ESG report. View the report here:
https://www.twistbioscience.com/company/esg?tab=environmental
1 Express Clonal Genes ship in 5-7 business days. DNA prep sizes
including 10 μg - 100 μg, and 100 μg - 1 mg may incur an additional
3-5 days for synthesis. Orders placed outside of the US will incur
additional delivery turnaround time. Express Genes orders that
require new custom vector onboarding will incur an additional 1-2
weeks for processing.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube |
Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
turnaround time of the Twist Express Gene offering for midiprep and
maxiprep DNA preparations, and Twist Bioscience’s ability to
service pharmaceutical, biotechnology, academic and industrial
chemical researchers using genes for large scale experimentation.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission on November 21,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124209204/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024